The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT00189839




Registration number
NCT00189839
Ethics application status
Date submitted
13/09/2005
Date registered
19/09/2005
Date last updated
9/07/2014

Titles & IDs
Public title
A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation
Scientific title
A Multicentre, Randomised, Double Blind, Two Arm Parallel Group Study to Evaluate and Compare the Efficacy and Safety of Modified Release Tacrolimus FK506E (MR4) Versus Tacrolimus FK506 in Combination With MMF (Cellcept®) and Steroids in Patients Undergoing Kidney Transplantation
Secondary ID [1] 0 0
FG-506E-12-03
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney Transplantation 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - tacrolimus

Active Comparator: 1 -

Experimental: 2 -


Treatment: Drugs: tacrolimus
Immunosuppression

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to and incidence of biopsy-proven acute rejections
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Overall rate of acute rejections
Timepoint [1] 0 0
12 months

Eligibility
Key inclusion criteria
- Patients receiving a kidney transplant from a cadaveric donor or a living non HLA
identical donor between 5 and 65 years of age with compatible ABO blood type.

- Patients with end stage kidney disease who are suitable candidates for primary renal
transplantation or re-transplantation (unless the graft was lost because of
immunological reasons within 12 months).
Minimum age
18 Years
Maximum age
65 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Patients receiving or having previously received an organ transplant other than a
kidney.

- Patients with a high immunological risk, defined as a panel reactive antibodies (PRA)
grade >50% in the previous 6 months and/or with a previous graft survival of less than
12 months due to immunological reasons.

- Cold ischaemia time of the donor kidney >30 hours.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Melbourne
Recruitment hospital [2] 0 0
- Sydney
Recruitment hospital [3] 0 0
- Westmead
Recruitment hospital [4] 0 0
- Woudville South
Recruitment postcode(s) [1] 0 0
- Melbourne
Recruitment postcode(s) [2] 0 0
- Sydney
Recruitment postcode(s) [3] 0 0
- Westmead
Recruitment postcode(s) [4] 0 0
- Woudville South
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Santa Fe
Country [3] 0 0
Austria
State/province [3] 0 0
Innsbruck
Country [4] 0 0
Belgium
State/province [4] 0 0
Bruxelles
Country [5] 0 0
Belgium
State/province [5] 0 0
Leuven
Country [6] 0 0
Brazil
State/province [6] 0 0
Campinas - SP
Country [7] 0 0
Brazil
State/province [7] 0 0
Porto Alegre
Country [8] 0 0
Brazil
State/province [8] 0 0
Rio de Janeiro - RJ
Country [9] 0 0
Brazil
State/province [9] 0 0
San Paulo - SP
Country [10] 0 0
Canada
State/province [10] 0 0
Nova Scotia
Country [11] 0 0
Canada
State/province [11] 0 0
Ontario
Country [12] 0 0
Canada
State/province [12] 0 0
Quebec
Country [13] 0 0
Czech Republic
State/province [13] 0 0
Praha 4
Country [14] 0 0
Finland
State/province [14] 0 0
Helsinki
Country [15] 0 0
France
State/province [15] 0 0
Creteil
Country [16] 0 0
France
State/province [16] 0 0
Grenoble
Country [17] 0 0
France
State/province [17] 0 0
Le Kremlin Bicetre Cedex
Country [18] 0 0
France
State/province [18] 0 0
Lille Cedex
Country [19] 0 0
France
State/province [19] 0 0
Montpellier Cedex 05
Country [20] 0 0
France
State/province [20] 0 0
Nantes Cedex 01
Country [21] 0 0
France
State/province [21] 0 0
Nice Cedex 1
Country [22] 0 0
France
State/province [22] 0 0
Saint-Etienne
Country [23] 0 0
France
State/province [23] 0 0
Toulouse Cedex 9
Country [24] 0 0
France
State/province [24] 0 0
Vandoeuvre les Nancy Cedex
Country [25] 0 0
Germany
State/province [25] 0 0
Berlin
Country [26] 0 0
Germany
State/province [26] 0 0
Bochum
Country [27] 0 0
Germany
State/province [27] 0 0
Erlangen
Country [28] 0 0
Germany
State/province [28] 0 0
Essen
Country [29] 0 0
Germany
State/province [29] 0 0
Frankfurt
Country [30] 0 0
Germany
State/province [30] 0 0
Halle
Country [31] 0 0
Germany
State/province [31] 0 0
Hann
Country [32] 0 0
Germany
State/province [32] 0 0
Koln
Country [33] 0 0
Germany
State/province [33] 0 0
Munchen
Country [34] 0 0
Germany
State/province [34] 0 0
Regensburg
Country [35] 0 0
Greece
State/province [35] 0 0
Athens
Country [36] 0 0
Greece
State/province [36] 0 0
Thessaloniki
Country [37] 0 0
Hungary
State/province [37] 0 0
Budapest
Country [38] 0 0
Ireland
State/province [38] 0 0
Dublin
Country [39] 0 0
Italy
State/province [39] 0 0
Bari
Country [40] 0 0
Italy
State/province [40] 0 0
Milano
Country [41] 0 0
Italy
State/province [41] 0 0
Padova
Country [42] 0 0
Italy
State/province [42] 0 0
Palermo
Country [43] 0 0
Italy
State/province [43] 0 0
Pisa
Country [44] 0 0
Italy
State/province [44] 0 0
Siena
Country [45] 0 0
Italy
State/province [45] 0 0
Treviso
Country [46] 0 0
Mexico
State/province [46] 0 0
Cuernavaca Morelos
Country [47] 0 0
Mexico
State/province [47] 0 0
Mexico D.F.
Country [48] 0 0
Netherlands
State/province [48] 0 0
Maastricht
Country [49] 0 0
Netherlands
State/province [49] 0 0
Utrecht
Country [50] 0 0
Norway
State/province [50] 0 0
Oslo
Country [51] 0 0
Poland
State/province [51] 0 0
Bydgoszcz
Country [52] 0 0
Poland
State/province [52] 0 0
Szczecin
Country [53] 0 0
South Africa
State/province [53] 0 0
Cape Town
Country [54] 0 0
South Africa
State/province [54] 0 0
Durban
Country [55] 0 0
South Africa
State/province [55] 0 0
Pretoria
Country [56] 0 0
Spain
State/province [56] 0 0
Badalona Barcelona
Country [57] 0 0
Spain
State/province [57] 0 0
Barcelona
Country [58] 0 0
Spain
State/province [58] 0 0
Cordoba
Country [59] 0 0
Spain
State/province [59] 0 0
La Coruna
Country [60] 0 0
Spain
State/province [60] 0 0
Madrid
Country [61] 0 0
Spain
State/province [61] 0 0
Malaga
Country [62] 0 0
Spain
State/province [62] 0 0
Santander
Country [63] 0 0
Spain
State/province [63] 0 0
Sevilla
Country [64] 0 0
Sweden
State/province [64] 0 0
Goteborg
Country [65] 0 0
Sweden
State/province [65] 0 0
Uppsala
Country [66] 0 0
Switzerland
State/province [66] 0 0
Zurich
Country [67] 0 0
United Kingdom
State/province [67] 0 0
Belfast
Country [68] 0 0
United Kingdom
State/province [68] 0 0
Birmingham
Country [69] 0 0
United Kingdom
State/province [69] 0 0
Coventry
Country [70] 0 0
United Kingdom
State/province [70] 0 0
Glasgow
Country [71] 0 0
United Kingdom
State/province [71] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Astellas Pharma Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate and to compare the efficacy and safety of a triple
modified release tacrolimus FK506E (MR4) / MMF / steroid regimen with a triple standard
tacrolimus FK506 / MMF / steroid regimen in patients undergoing kidney transplantation. It
shall be demonstrated that FK506E (MR4) is non-inferior to FK506 with regards to the primary
endpoint.
Trial website
https://clinicaltrials.gov/show/NCT00189839
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
B Krämer
Address 0 0
Klinikum der Universität Regensburg
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications